The Maternal Phenylketonuria International Study: 1984-2002.

Pediatrics 2003 Dec;112(6 Pt 2):1523-9

Childrens Hospital of Los Angeles and the University of Southern California School of Medicine, Los Angeles, California 90027, USA.

Objective: The purpose of this report is to review the obstetric medical, psychological, and nutritional aspects and outcome of the women and offspring enrolled in the Maternal Phenylketonuria Study, which was established to assess the efficacy of a phenylalanine (Phe)-restricted diet in preventing the morbidity associated with this disorder.

Methods: A total of 382 women with hyperphenylalaninemia (HPA) were enrolled in the study and completed 572 pregnancies. Outcome measures were analyzed with chi2, Fisher exact text, analysis of variance, t test, Wilcoxon nonparametric test, and multiple logistic regression. Outcome measures were stratified according to maternal HPA classification and the time when dietary control was achieved.

Results: Optimal birth outcomes occurred when maternal blood Phe levels between 120 and 360 micromol/L were achieved by 8 to 10 weeks of gestation and maintained throughout pregnancy (trimester averages of 600 micromol/L). Mothers with mild HPA achieved similar birth outcomes as mothers who were in control preconceptually and those in control by 8 to 10 weeks of pregnancy.

Conclusions: Before conception, counseling and early entrance into a prenatal care program is essential in achieving optimal fetal outcome in women with HPA. The achievement of pre- and periconceptional dietary control with a Phe-restricted diet significantly decreased morbidity in the offspring of women with HPA.

Download full-text PDF

Source
December 2003

Publication Analysis

Top Keywords

outcome measures
8
birth outcomes
8
outcome women
8
women hpa
8
maternal phenylketonuria
8
dietary control
8
phe-restricted diet
8
hpa
5
outcomes occurred
4
control achievedresults
4
achievedresults optimal
4
occurred maternal
4
optimal birth
4
blood phe
4
360 micromol/l
4
micromol/l achieved
4
achieved weeks
4
120 360
4
levels 120
4
control
4

Similar Publications

Role of nutrition in pregnancy with phenylketonuria and birth defects.

Pediatrics 2003 Dec;112(6 Pt 2):1534-6

Department of Health and Human Performance, University of Houston, Houston, Texas 77204-6020, USA.

Objective: The maternal phenylketonuria (PKU) syndrome is caused by high blood phenylalanine (Phe) levels during pregnancy, leading to a host of birth defects, especially microcephaly and congenital heart disease (CHD). For finding whether the maternal PKU syndrome could be prevented, an international collaborative study was organized to evaluate treatment with a Phe-restricted diet. Blood Phe levels, maternal weight gain, and nutrient intakes during pregnancy were evaluated as to their effect on the rate of microcephaly and CHD in the offspring. Read More

View Article and Full-Text PDF
December 2003

Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy.

J Pediatr 2004 Feb;144(2):235-9

Children's Hospital University of Texas Medical Branch, Department of Pediatrics, Galveston, Texas 7555-0359, USA.

Objectives: The Maternal Phenylketonuria Study was designed to determine the effect of a phenylalanine (Phe)-restricted diet in reducing the morbidity on the fetus. Congenital abnormalities were noted, with the focus on the effect of congenital heart defects (CHDs) and microcephaly (MICRO) on developmental outcome at 4 and 6 years of age.

Study Design: Women with blood Phe levels >240 micromol/L (n=526; to convert micromol/L to mg/dL, divide by 60) were enrolled; 382 contributed 572 pregnancies. Read More

View Article and Full-Text PDF
February 2004

Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.

Pediatrics 2003 Dec;112(6 Pt 2):1530-3

Department of Inherited Metabolic Disease and Molecular Genetics, The John F. Kennedy Institute, Glostrup, Denmark.

Objective: The aim of the present study was to examine to what extent maternal and offspring phenylalanine hydroxylase (PAH) genotypes in conjunction with maternal IQ and dietary control during pregnancy are related to cognitive development in offspring of women with phenylketonuria (PKU).

Methods: PAH gene mutations were determined in 196 maternal PKU subjects and their offspring. The women were grouped according to PAH genotype, which predicts the metabolic phenotype (severe PKU, mild PKU, and mild hyperphenylalaninemia [MHP]). Read More

View Article and Full-Text PDF
December 2003

Pregnancy experiences in the woman with mild hyperphenylalaninemia.

Pediatrics 2003 Dec;112(6 Pt 2):1548-52

Division of Genetics, Children's Hospital Boston, Boston, Massachusetts 02115, USA.

Objective: A major issue in maternal phenylketonuria (MPKU) has been whether maternal non-PKU mild hyperphenylalaninemia (MHP) is teratogenic. Such untreated pregnancies and their outcomes are presented on this report.

Methods: Enrolled pregnancies in which the untreated prepregnancy assigned phenylalanine level (APL) was no more than 600 micro mol/L were included in the Maternal PKU Collaborative Study and were followed according to protocol. Read More

View Article and Full-Text PDF
December 2003